Responses
Clinical aspects
Comparison of the efficacy of the tumour necrosis factor α blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis
Compose a Response to This Article
Other responses
No responses have been published for this article.